Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.

Longjiang ShaoNermin KahramanGe YanJianghua WangBulent OzpolatMichael M Ittmann

Published in: The Prostate (2019)

TE-targeted gene silencing therapy using liposomal nanovectors is a potential therapeutic strategy as a monotherapy and to enhance the efficacy of chemotherapy in patients with advanced PCa.

Keyphrases

prostate cancer
cancer therapy
combination therapy
locally advanced
randomized controlled trial
clinical trial
stem cells
rectal cancer
smoking cessation